AZD 8529

Drug Profile

AZD 8529

Alternative Names: AZD-8529

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator AstraZeneca
  • Class Neuropsychotherapeutics; Small molecules
  • Mechanism of Action Glutamate modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Schizophrenia

Most Recent Events

  • 17 Mar 2015 National Institute on Drug Abuse plans a phase II trial for Smoking withdrawal in USA (NCT02401022)
  • 03 May 2011 AstraZeneca completes its phase 0 trial in healthy volunteers in the US [completion after discontinuation] (NCT00985933)
  • 09 Mar 2011 AstraZeneca completes enrolment in its phase 0 trial in healthy volunteers in the US (NCT00985933)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top